Can cosentyx lead to weight loss in patients?

Can Cosentyx cause weight loss?

Cosentyx (secukinumab) is an IL-17A inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Clinical trials did not list weight loss as a common side effect. Patients report mixed experiences, with some noting modest weight reduction and others gaining weight. No large studies confirm a direct causal link.

Why do some patients lose weight on Cosentyx?

Reduced joint pain and skin inflammation can increase mobility, leading to more physical activity. In a small number of cases, gastrointestinal upset or appetite changes occur, though these effects are uncommon and usually mild. The mechanism is not well defined, and weight loss is not considered a predictable outcome.

How does Cosentyx compare to other IL-17 or TNF inhibitors regarding weight?

TNF inhibitors such as adalimumab and etanercept are more consistently linked to weight gain. IL-17 inhibitors like Cosentyx and Taltz show fewer reports of weight increase, but neither class reliably produces weight loss. Head-to-head data on this outcome are limited.

What should patients monitor if weight changes occur?

Track weight monthly and note any accompanying symptoms such as fatigue, diarrhea, or new infections. Sudden or significant loss warrants evaluation for other causes, including infection or unrelated gastrointestinal disease. Dose adjustments or switching therapies are rarely driven by weight alone.

When do patents for Cosentyx expire?

The composition-of-matter patent for secukinumab expires in 2029 in the United States, with some formulation patents extending to 2031. Biosimilar entry is expected after these dates, though litigation could shift the timeline. DrugPatentWatch.com lists detailed patent and exclusivity data for Cosentyx.